Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Relu Cernes, Margarita Mashavi, Reuven Zimlichman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8-32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.

Original languageEnglish
Pages (from-to)749-759
Number of pages11
JournalVascular Health and Risk Management
Volume7
Issue number1
DOIs
StatePublished - 2011
Externally publishedYes

Keywords

  • Angiotensin receptor blockers
  • Blood pressure
  • Candesartan
  • Candesartan cilexetil
  • Clinical trials
  • Efficacy studies
  • Safety

Fingerprint

Dive into the research topics of 'Differential clinical profile of candesartan compared to other angiotensin receptor blockers'. Together they form a unique fingerprint.

Cite this